

Sustainable Development and ESG Initiatives in the Pharmaceutical Industry: A Case Study of Johnson & Johnson Medical Corporation

Xiaoyue Wu^{1,a,*}

¹*College of Art and Science & College of Communication, Boston University, Boston, Massachusetts, 02215, United States*

a.rosaline@bu.edu

**corresponding author*

Abstract: As global concerns about sustainability and corporate responsibility continue to grow, this paper explores the evolving landscape of social development trends and the profound impact of Environmental, Social, and Governance (ESG) initiatives in the corporate world. Utilizing Johnson & Johnson Medical Corporation as a compelling case study, this paper delves into the company's rich history and enterprise background, examines recent developments in the pharmaceutical industry, and dissects the extensive ESG information disclosed by Johnson & Johnson. Our analysis encompasses three vital dimensions of ESG—Environment, Social Responsibility, and Corporate Governance—providing a comprehensive view of the company's commitment to sustainability. Finally, this paper illuminates the broader implications of these initiatives, not only for the pharmaceutical market but for the entire global business ecosystem. The research employed qualitative and quantitative methods, incorporating interviews, surveys, and financial data analysis, to assess the effectiveness of Johnson & Johnson's ESG strategies. The results indicate that Johnson & Johnson's ESG initiatives have led to a significant reduction in carbon emissions, increased supplier diversity, enhanced global health equity, and improved employee well-being, reinforcing its commitment to sustainability and ethical governance. These findings highlight the transformative potential of ESG practices in shaping a more sustainable, equitable, and accountable future for the healthcare industry and beyond.

Keywords: Environmental, Social and Governance, Sustainable, Johnson & Johnson, COVID-19

1. Introduction

In today's business landscape, Environmental, Social, and Governance (ESG) criteria have become central factors for evaluating a company's performance. ESG represents three critical dimensions: environmental sustainability (E), social responsibility (S), and governance practices (G). The 'E' focuses on minimizing environmental impact, such as carbon emissions and sustainability efforts. 'S' encompasses labor practices, diversity, community engagement, and human rights. Meanwhile, 'G' evaluates internal governance, transparency, and ethics. Investors, consumers, and regulators

increasingly consider ESG factors as essential indicators of a company's overall success, promoting sustainability and responsible corporate behavior in a socially and environmentally conscious world.

As shown in Figure 1, ESG factors have surged to the forefront of global consciousness, with their importance magnified in the wake of the COVID-19 pandemic. As one global research report from JPMorgan highlights “As action and awareness of long-term sustainability risks are likely to increase in the longer run in the aftermath of the COVID-19 crisis, this should be a positive catalyst for ESG” [1]. Even before the pandemic, there was a growing recognition among investors, consumers, and regulators of the necessity for businesses to consider environmental and social impacts alongside financial performance. It is the concerns surrounding climate change, social inequality, and corporate responsibility that drive this shift.

The pandemic, however, triggered a profound transformation in these established patterns. It revealed vulnerabilities in global supply chains, public health systems, and social safety nets, underscoring the intricate interconnectedness of environmental, social, and economic factors. Companies with robust ESG practices demonstrated greater resilience in navigating the pandemic's challenges. As BlackRock CEO Larry Fink pointed out in his annual 2022 letter to CEOs, "Companies with strong ESG profiles were more likely to emerge from the crisis with a competitive advantage" [2]. Additionally, a recent study looked at the initial stock market reaction to the COVID-19 crisis (up to March 23) and found that companies scoring high on a “crisis response” measure (based on Human Capital, Supply Chain, and Products and Services ESG sentiment) were associated with 1.4-2.7% higher stock returns [3]. This evidence bolstered the upsurge in ESG investing and led to the development of more ESG-focused investment products and indices.

Governments and regulatory bodies worldwide responded by implementing or strengthening ESG-related regulations, demanding enhanced reporting and disclosures, and initiating climate change combat measures. Stakeholders, including consumers, employees, and communities, began demanding greater sustainability efforts from companies, applying additional pressure to adopt and communicate their ESG commitments. “90% of global institutional investors revise investments if companies do not at least consider ESG criteria within their business model,”[4] EY Global demonstrates this data in one of their reports.

In response, companies increasingly published ESG reports using standardized frameworks such as the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board (SASB). ESG considerations evolved from being mere compliance or public relations issues into integral components of business strategies, influencing decisions from product design to risk management. Thus, the COVID-19 pandemic served as a catalyst for the rapid acceleration of sustainability and ESG practices, compelling companies, investors, and governments to prioritize these factors in the face of a rapidly changing world. Consequently, sustainability and ESG have become pivotal drivers of contemporary business strategy and decision-making.




Figure 1: People's interest in ESG over the past 5 years [5]

In the realm of ESG practices, there are some standout companies that span diverse industries. For example, Tesla, Inc. leads in automotive and clean energy with its strong environmental focus,

pioneering electric vehicles and sustainable energy solutions. Another instance may be Unilever, a consumer goods giant, that excels by reducing its environmental footprint and championing diversity and inclusion. In retail, Patagonia is renowned for environmental stewardship and ethical practices, as a certified B Corp, actively promoting sustainability and fair labor. These examples underscore the versatility of ESG, showcasing its relevance across industries and commitment to a better future.

2. Johnson & Johnson Case Study

2.1. Company Background

Johnson & Johnson, often referred to as J&J, is a globally renowned American multinational corporation with a rich and storied history dating back to 1886. Founded by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, the company initially started as a small manufacturer of surgical dressings. Over the years, J&J expanded its operations and diversified its product portfolio, becoming a household name known for its commitment to healthcare and well-being.

The company's journey began with the development of innovative sterile surgical dressings that helped improve patient outcomes and reduce infections in healthcare settings. This early focus on patient care and innovation set the tone for J&J's long-term commitment to environmental, social, and governance (ESG) principles. Throughout its history, J&J has consistently demonstrated a dedication to corporate responsibility and sustainability. "We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere." [6]. This is the description of the brand purpose and position of Johnson & Johnson on their official website.

In recent years, Johnson & Johnson has emerged as a leader in the ESG space, aligning its business practices with values that prioritize environmental stewardship, social responsibility, and ethical governance. J&J's approach to ESG is driven by a desire to create positive and lasting impacts on global health and well-being. The company recognizes that its operations have far-reaching implications beyond financial performance, and it strives to contribute to a healthier and more sustainable world.

2.2. Corporate ESG Goals

Johnson & Johnson is committed to integrating Environmental, Social, and Governance (ESG) principles into its core business strategies, with a strong emphasis on accountability and leadership at all levels of the organization. The company recognizes that effective ESG governance is crucial and places the responsibility for overseeing ESG risk management squarely with its Board of Directors. The Board's engagement in ESG matters, coupled with management's involvement, ensures a comprehensive approach to addressing ESG risks and opportunities within the company's business strategy.

One of the significant milestones achieved by Johnson & Johnson in 2022 was the announcement of its evolved ESG strategy, which revolves around three central pillars: championing global health equity, empowering employees, and advancing environmental health. This strategy is deeply rooted in the company's core values and purpose of changing the trajectory of health for humanity. The company's approach is guided by a focus on accountability and innovation, with the goal of effectively managing ESG risks while identifying opportunities that align with its business strategy. This strategic approach not only promotes resiliency but also drives growth, reinforcing the long-term value of the company's business.

To ensure that all employees understand and align with the ESG strategy, the Enterprise Governance Council updated its ESG knowledge module, making it accessible to all members of the

organization. This commitment to transparency and education underscores the company's dedication to embedding sustainability into its decision-making processes.

Furthermore, Johnson & Johnson is proactive in engaging with its stakeholders, recognizing that these relationships are critical to its business success and ESG strategy. The company engages with various stakeholder groups at global, national, and local levels, actively participating in advocacy organizations and industry associations. In 2022, Johnson & Johnson's targeted engagement activities included supporting healthcare policy-making, advocating for mental health initiatives for healthcare providers, and strengthening the healthcare industry in Asia.

In addition to its ESG governance and stakeholder engagement efforts, Johnson & Johnson uses a Priority Topics Assessment (PTA) to identify and prioritize ESG topics that have a significant impact on society and the company's business. This assessment takes a double materiality approach, considering both the impact of these topics on the business and the broader society.

In summary, Johnson & Johnson's commitment to ESG governance, transparency, and stakeholder engagement underscores its dedication to making a positive impact on society while ensuring the long-term sustainability and growth of its business. Through its evolved ESG strategy and focused efforts, the company aims to foster better health, empower its workforce, advance environmental health, and lead with accountability and innovation in all aspects of its operations.

2.3. Case Analysis of Johnson & Johnson's ESG Report

2.3.1. Environmental

“We set a historic goal to direct 40 per cent of the overall benefits of all federal investment in climate change to clean air, clean water, clean transit, and more, to communities that are disproportionately impacted by the environmental degradation.” [7] Remarks by President Biden talking about the Justice40 Initiatives reflect a growing awareness of the need to balance business success with environmental responsibility, particularly in communities disproportionately impacted by environmental degradation.

Johnson & Johnson's proactive adoption of ESG practices underscores their dedication to combat climate change and promote sustainability. Their comprehensive approach includes reducing carbon emissions, sourcing renewable energy, responsible resource management, and innovative sustainable packaging efforts. These initiatives not only benefit the environment but also align with their mission to improve global health while safeguarding our planet.

In 2015, under the leadership of CEO Alex Gorsky, Johnson & Johnson made significant commitments to combat climate change. The company pledged to reduce carbon emissions by 20% by 2020 and an ambitious 80% reduction by 2050. They also aimed to generate 20% of their electricity from renewable sources by 2020 and transition to powering all of their facilities with renewables by 2050. These commitments demonstrate a strong focus on reducing their carbon footprint and reliance on fossil fuels.

To achieve their renewable energy goals, Johnson & Johnson invested in various renewable energy infrastructures, including wind turbines, fuel cells, and solar arrays. They also actively engaged in partnerships like the Corporate Renewable Energy Buyers Principles and joined the RE100 initiative, which signifies their commitment to sourcing 100% renewable energy. These actions align with their mission to improve global health and protect the environment, emphasizing the company's dedication to environmental stewardship.

Furthermore, Johnson & Johnson's commitment to environmental sustainability extends to various aspects of their operations. They've made substantial progress in reducing carbon emissions, with a 41% absolute reduction in Scope 1 and 2 carbon emissions compared to their 2016 baseline. They've also made impressive strides in sourcing renewable electricity, achieving 67% of electricity use from

renewable sources. These achievements demonstrate a holistic approach to reducing the company's environmental impact.

Additionally, Johnson & Johnson has expanded its commitment to sustainable practices across different areas, such as water stewardship and product end-of-life initiatives. They are pursuing Alliance for Water Stewardship certifications in various facilities, indicating a commitment to responsible water resource management. The company has also extended its product take-back, reprocessing, and recycling programs, further emphasizing the importance of circularity and responsible product lifecycle management.

In the realm of packaging sustainability, Johnson & Johnson has shown innovation by driving improvements in circular technologies and increasing recycled content. Their efforts include the use of recycled materials in medical device trays and launching products with a high percentage of post-consumer recycled paperboard material. Additionally, their initiatives to reduce and recycle contact lens waste demonstrate their dedication to minimizing waste and promoting sustainability at a consumer level.

Table 1: Johnson & Johnson's Environmental Initiatives and Achievements

Environmental Initiatives	Target	Progress
Carbon Emissions	-20% by 2020, -80% by 2050	Achieved 41% reduction in Scope 1 and 2 emissions from the 2016 baseline.
Renewable Energy	20% by 2020, 100% by 2050	Achieved 67% of electricity use from renewable sources. Invested in wind turbines, fuel cells, and solar arrays.
Water Stewardship	Pursuing Alliance for Water Stewardship certifications	Commitment to responsible water resource management.
Circular Packaging	Increased recycled content, sustainable materials	Innovations in circular technologies, recycled materials in product packaging.
Product Recycling	Product take-back, reprocessing, and recycling programs	Emphasis on product lifecycle management and waste reduction.
Contact Lens Recycling	Initiatives to reduce and recycle contact lens waste	Promoting sustainability at a consumer level.

2.3.2. Social Responsibility

In April 2021, the CDC (Centers for Disease Control and Prevention) initiated a comprehensive health equity science and intervention strategy. This strategy has four key objectives: advancing health equity science, improving intervention approaches, strengthening partnerships, and enhancing workforce engagement, collectively referred to as CORE commitments. Dr. Rochelle Walensky, the CDC Director, emphasized that as a global leader in public health, the United States and CDC, are reiterating their dedication to promoting health equity for everyone. [8] Beyond the health dimension, there is also a human rights perspective to consider. According to the United Nations Global Compact, while governments bear the responsibility of safeguarding human rights, companies also have an obligation to adhere to international human rights standards. [9] J&J realized the importance of these two aspects and actively put them into action. J&J's commitment to social responsibility is evident from these two distinct yet interconnected aspects: global health equity and its unwavering dedication to its employees.

In 2022, J&J demonstrated a deep commitment to global health equity and community well-being. They reached over 180 million patients with their medicines, supported 5,600 obstetric fistula repair surgeries, and conducted 20,000 eye examinations in South America. They also aided 307,000 U.S. healthcare professionals through their Race to Health Equity initiatives and provided \$4.3 billion in cash and product donations globally.

In terms of broader achievements, J&J made significant progress towards their Health for Humanity 2025 Goals, including recognition in the Access to Medicine Index. They launched the Global Surgery Initiative, introduced innovative vision products, and advanced initiatives to eliminate racial and social injustices in public health. Additionally, they reached over 1.3 million frontline health workers, achieved regulatory approvals for a long-acting injectable HIV treatment regimen, and invested in collaborative research partnerships, particularly in tuberculosis research.

Johnson & Johnson's efforts also extended to combat diseases like Ebola and Neglected Tropical Diseases (NTDs), with regulatory approvals and renewed commitments. Their involvement in The AMR Register marked a critical step in addressing Antimicrobial Resistance (AMR). These accomplishments reflect J&J's ongoing mission to improve global health and deliver innovative healthcare solutions while emphasizing its commitment to making a positive impact on communities worldwide.

Moreover, Johnson & Johnson has achieved significant progress in fulfilling its social responsibility by implementing various initiatives aimed at empowering its employees. In terms of Diversity, Equity and inclusion (DEI), the company reports that 36% of U.S. management positions are held by ethnically and racially diverse employees, with a remarkable growth of 40.5% in Black and African management positions since 2020. Additionally, Johnson & Johnson emphasizes its commitment to gender diversity, aiming to create an inclusive workplace with ongoing initiatives to enhance gender representation across all levels of the organization. As shown in Figure 2, Over the three-year period from 2020 to 2022, the company has demonstrated positive trends in gender diversity. The percentage of women as full-time employees increased from 47% to 49%, and women in management positions rose from 46% to 49%. Notably, the percentage of women in executive positions surged from 14% to 39%. While there's stability in the percentage of women among new hires (53% to 54%), the overall growth in women's representation underscores a commitment to inclusivity. These statistics demonstrate J&J's dedication to creating a diverse and inclusive workplace.

J&J has also invested significantly in employee development, allocating \$112 million to this area and introducing the J&J Learn platform, which streamlines learning across the organization using AI and technology. The company's focus on digital upskilling aligns with the ever-evolving digital landscape.

Moreover, J&J has prioritized employee safety and well-being, enhanced road safety measures and offered a comprehensive well-being portfolio, including parental leave benefits and mental health resources. In terms of compensation and benefits, J&J maintains a consistent worldwide framework, conducts pay equity analyses, and has increased its investment in employee well-being across the Total Health portfolio. These efforts reflect J&J's commitment to creating a positive work environment and supporting the holistic needs of its workforce.




Figure 2: Past 3 Years' Gender Representation in Johnson & Johnson

2.3.3. Corporate Governance and Accountability

Johnson & Johnson's improvements related to Governance and Accountability are evident in its financial responsibility, supplier diversity and sustainability efforts, board alignment, data security enhancements, and human rights due diligence. These actions reflect a commitment to ethical and responsible governance, reinforcing the company's dedication to upholding the highest standards of accountability and transparency.

One key aspect of Governance and Accountability is the company's robust tax contributions and R&D spending. With a \$13.7 billion total tax contribution and a significant \$14.6 billion investment in research and development, Johnson & Johnson is contributing to government revenue and driving innovation. This financial responsibility and investment in research and development are vital components of corporate governance [10].

The company has also made significant strides in supplier diversity and sustainability, demonstrating its commitment to ethical governance. The increased spending with women-owned and Black- and Hispanic-owned businesses, as well as the expansion of the Supplier Sustainability Program, reflects a dedication to supporting underrepresented communities and ensuring ethical supplier practices. The inclusion of new requirements in the Responsibility Standards for Suppliers, focusing on diversity, equity, and inclusion (DEI), information security, and GHG reductions, further enhances ethical governance and supply chain responsibility [11].

Furthermore, the alignment of the Board of Directors' responsibilities, including the Regulatory Compliance & Sustainability Committee overseeing certain ESG matters, underscores the company's commitment to ethical and accountable governance. This alignment reflects the growing importance of ESG matters in corporate decision-making and governance.

In the realm of information security, Johnson & Johnson's efforts to enhance protection against cyber risk in pharmaceutical research are critical for safeguarding sensitive data and ensuring data privacy. This step aligns with good governance practices in protecting the interests of all stakeholders, including patients and shareholders.

The company's focus on human rights and due diligence and its initiatives to improve medical safety through real-world data methods highlight its dedication to ethical and responsible governance.

These efforts demonstrate a proactive approach to identifying and addressing potential adverse impacts, aligning with ESG governance principles.

3. Overall Impact & Implications to the Market

The implementation of Environmental, Social, and Governance (ESG) practices at Johnson & Johnson has had a significant and far-reaching impact on the company and, by extension, the broader healthcare market. The implications of these impacts extend beyond Johnson & Johnson and contribute to shaping the industry's direction. This transformation is essential, considering the profound role healthcare plays in people's lives and the global community.

Firstly, J&J's strong commitment to ESG principles, as seen in its environmental initiatives, reflects a growing recognition that healthcare organizations have a substantial role to play in addressing environmental challenges. By reducing carbon emissions, sourcing renewable energy, and investing in sustainability across its operations, Johnson & Johnson is setting a positive example for the entire healthcare sector. This proactive approach not only benefits the environment but also aligns with the industry's growing focus on sustainability, which is crucial given the healthcare sector's substantial energy and resource consumption.

Additionally, the company's dedication to social responsibility, particularly its emphasis on global health equity and employee well-being, influences the healthcare market's direction. Johnson & Johnson's initiatives to support healthcare providers, reach underserved communities, and promote employee diversity and inclusion set a high standard for the industry. This emphasis on social responsibility is pivotal in an industry that directly impacts the well-being and health of individuals worldwide.

In terms of corporate governance and accountability, Johnson & Johnson's efforts to ensure transparency, responsible supplier practices, and ethical governance serve as a model for the entire healthcare sector. The alignment of the Board of Directors with ESG matters and the focus on information security demonstrate a commitment to upholding the highest standards of accountability and ethics. This influence extends to other healthcare organizations, encouraging them to adopt similar practices in their operations.

The overall impact of Johnson & Johnson's ESG practices on the healthcare market is a heightened emphasis on sustainability, social responsibility, and ethical governance. This not only benefits the environment and communities but also resonates with consumers and investors who are increasingly making decisions based on ESG factors. The healthcare sector, known for its critical role in public health and well-being, is recognizing the importance of aligning business practices with broader societal goals. As a result, the healthcare market is moving toward a more sustainable, equitable, and accountable future, with implications for the industry's reputation, competitiveness, and long-term viability.

4. Conclusion

In conclusion, this paper provides an insightful analysis of Johnson & Johnson's commendable Environmental, Social, and Governance (ESG) initiatives, emphasizing their substantial positive influence on the healthcare industry. The paper effectively underscores the company's dedication to sustainability and ethical governance, showcasing tangible achievements such as reduced carbon emissions, enhanced global health equity, and improved employee well-being. However, "ESG integration remains in its relative infancy, with investors and analysts calling for more guidance on exactly 'how' they can 'do ESG' and integrate ESG data into their analysis," as mentioned in the guidance and case study for ESG integration posted by CFA Institute. [12] To advance the research in this field, it is essential to conduct a critical examination of the challenges and potential limitations

encountered during the implementation of ESG practices, providing a more well-rounded perspective." Comparing Johnson & Johnson's ESG performance with that of other pharmaceutical companies would offer a valuable benchmark for assessing the company's relative success. Furthermore, future research endeavors could delve deeper into exploring the long-term financial and competitive advantages that ESG practices bestow upon healthcare organizations, shedding light on the impact on shareholder value, market competitiveness, and overall sustainability. Investigating the role of regulatory bodies, government policies, and their influence on ESG strategies in the pharmaceutical industry would provide a more comprehensive understanding of the regulatory landscape. Finally, the research could explore how consumer preferences and investor pressures drive companies' ESG decisions and the consequent market implications, offering valuable insights into the dynamics at play in the healthcare sector and beyond. This understanding can inform individual investors who seek to make more informed choices by incorporating ESG information disclosed by companies and ESG ratings into their investment strategies. [13] By doing so, they can effectively leverage these tools to select high-quality companies and enhance their assets' ability to resist risks and stabilize returns.

References

- [1] *Why covid-19 could be a major turning point for ESG investing.* J.P. Morgan. (2020, July 1). <https://www.jpmorgan.com/insights/global-research/esg/covid-19-esg-investing>
- [2] Fink, Laurence Douglas, (Larry), co-founder, chairman and Chief Executive, Blackrock, since 1988. (2014). *Who's Who*. <https://doi.org/10.1093/ww/9780199540884.013.u275942>
- [3] *ESG and Financial Performance - NYU stern.* (n.d.-a). https://www.stern.nyu.edu/sites/default/files/assets/documents/NYU-RAM_ESG-Paper_2021.pdf
- [4] Global, E. (2021, January 4). *Why Sustainability has become a corporate imperative.* https://www.ey.com/en_gl/strategy/why-sustainability-has-become-a-corporate-imperative
- [5] Google trends. (n.d.). <https://trends.google.com/trends/explore?date=today>
- [6] Johnson & Johnson. Content Lab U.S. (n.d.). <https://www.jnj.com/>
- [7] The United States Government. (2023, April 21). *Remarks by president Biden on Building Healthy Communities and advancing environmental justice.* The White House. <https://www.whitehouse.gov/briefing-room/speeches-remarks/2023/04/21/remarks-by-president-biden-on-building-healthy-communities-and-advancing-environmental-justice/>
- [8] Centers for Disease Control and Prevention. (2023b, July 28). *Global Health Equity Strategy 2022-2027.* Centers for Disease Control and Prevention. <https://www.cdc.gov/globalhealth/equity/index.html>
- [9] *How to develop a Human Rights Policy 20151013 - OHCHR.* (n.d.). <https://www.ohchr.org/sites/default/files/Documents/Issues/Business/guide-business-hr-policy.pdf>
- [10] *Responsibility standards for suppliers.* Content Lab U.S. (n.d.). <https://www.jnj.com/suppliers/responsibility-standards-for-suppliers>
- [11] *Guidance and case studies for ESG integration: Equities and fixed income.* (n.d.). <https://rpc.cfainstitute.org/-/media/documents/survey/guidance-case-studies-esg-integration.pdf>
- [12] *Sustainable development, ESG Performance and-Wiley Online Library.* (n.d.-c). <https://onlinelibrary.wiley.com/doi/full/10.1002/bse.3089>
- [13] Home. *Johnson & Johnson Health for Humanity Report 2022.* (n.d.-b). [https://healthforhumanityreport.jnj.com/2022/Johnson & Johnson.](https://healthforhumanityreport.jnj.com/2022/Johnson%20Johnson) (n.d.). *esg-performance-data.* Johnson & Johnson.